


REMARKS

As applicants have previously explained, all the claims examined in this application, at all times, have not been indefinite. A skilled worker would have no difficulty in knowing what is and what is not covered by any of the claims, especially in conjunction with details of the specification. Similarly, to the extent a claim covers prevention, that claim is fully enabled by the specification in view of the well-known state of the art wherein heparin is commonly used for precisely such purposes, as already established of record. Lastly, with respect to the examiner's statement with respect to use of the term "modified" in other documents, to the extent any other document has a filing date equivalent to that of this application and a similar specification, that document meets all requirements of 35 USC 112. Nevertheless, in order to expedite prosecution, applicants have cancelled claims 9-41, as well as claims 46-48.

As for the double patenting rejection of claims 50-62, note that the terminal disclaimer already of record applies to all claims of this application no matter when those claims are pending. Thus, this rejection is now moot.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: GLYCO-0012-C02

Date: October 10, 2006
AJZ:hlw K:\Glyco\12C2\REPLY 10.10.06.doc